1. THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE‐2 TRIAL. (12th June 2019) Authors: Tiacci, E.; De Carolis, L.; Simonetti, E.; Zaja, F.; Capponi, M.; Ambrosetti, A.; Lucia, E.; Antolino, A.; Pulsoni, A.; Ferrari, S.; Zinzani, P.; Rigacci, L.; Gaidano, G.; Della Seta, R.; Frattarelli, N.; Falcucci, P.; Visani, G.; Foà, R.; Falini, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗